Pathways’ Picks November 17: Big Week in Washington, Aussie Reclassifications, China Picks, and More

article image

In this week’s roundup: Looking for upclassifications in six important device categories in Australia; MCIT repeal will lead to stakeholder meetings and potential congressional action; Cures 2.0, real world evidence, and decentralized trials; Califf nomination; FDA COVID-19 diagnostic updates; China targets next-gen sequencing standards, digital therapeutics, and more.

Next Picks

What we’re watching for:

Australia reclassifications. New rules underlying risk classifications for multiple device categories are set to kick in on November 25 in Australia. In general, the changes will result in higher risk classes for six targeted device categories:


This article is restricted to subscribers only.

Sign in to continue reading.


We're here to help! Please contact us at: